Autoimmune hepatitis: Focusing on treatments other than steroids

Canadian Journal of Gastroenterology

Volumn 26, Issue 9, 2012, Pages 615-620

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autoimmune; Front line; Hepatitis; Molecular; Salvage; Therapy

Indexed keywords

AMINOTRANSFERASE; AZATHIOPRINE; BUDESONIDE; CD20 ANTIBODY; CYCLOSPORIN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT INTERLEUKIN 10; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AUTOIMMUNE HEPATITIS; CHILL; CORTICOSTEROID THERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; EPSTEIN BARR VIRUS INFECTION; FATIGUE; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; LEUKOPENIA; LUNG DISEASE; MYALGIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84866770664     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/512132     Document Type: Review

References (58)

1. Manns MP, Czaja AJ, Gorham JD, et al. Practice Guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-213.
2. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971;40:159-85.
3. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 1972;63:820-33.
4. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1:735-7.
5. Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): A single center experience. Z Gastroenterol 2001;39:339-41,44-8.
6. Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009;51:161-7.
7. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848-57. (Pubitemid 26071852)
8. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40:646-52. (Pubitemid 38367787)
9. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci 2005;50:547-51. (Pubitemid 40543746)
10. Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008;7:319-33. (Pubitemid 351802831)
11. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007;46:1138-45. (Pubitemid 350144778)
12. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984;4:622-7. (Pubitemid 14051128)
13. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983;3:685-9. (Pubitemid 13007694)
14. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: A retrospective analysis. Hepatology 2002;35:890-7. (Pubitemid 34258384)
15. Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol 2009;3:269-91.
16. Czaja AJ. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci 2010;55:2712-26.
17. Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Design 2011;17:3120-40.
18. Czaja AJ. Animal models of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol 2010;4:429-43.
19. Allison AC. Immunosuppressive drugs: The first 50 years and a glance forward. Immunopharmacology 2000;47:63-83. (Pubitemid 30394533)
20. Mistilis SP, Vickers CR, Darroch MH, McCarthy SW. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust 1985;143:463-5. (Pubitemid 16189821)
21. Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987;93:890-3. (Pubitemid 17156017)
22. Person JL, McHutchison JG, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol 1993;17:317-20. (Pubitemid 23360387)
23. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994;21:1040-7.
24. Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995;36:459-61.
25. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999;94:241-8. (Pubitemid 29063476)
26. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001;46:1321-7. (Pubitemid 32523281)
27. Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: A potential new treatment for autoimmune chronic active hepatitis: Results of an open-label preliminary trial. Am J Gastroenterol 1995;90:771-6.
28. Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004;38:805-9. (Pubitemid 39274185)
29. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007;13:3232-6. (Pubitemid 47064587)
30. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118. (Pubitemid 30394534)
31. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-5. (Pubitemid 30663373)
32. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004;18:321-6. (Pubitemid 38801788)
33. Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: The Canadian Association for the Study of the Liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005;25:723-7. (Pubitemid 41038652)
34. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: Comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005;39:819-25. (Pubitemid 41361901)
35. Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007;5:799-802. (Pubitemid 47031057)
36. Hlivko JT, Shiffman ML, Stravitz RT, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008;6:1036-40.
37. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008;103:3063-70.
38. Wolf DC, Bojito L, Facciuto M, Lebovics E. Mycophenolate mofetil for autoimmune hepatitis: A single practice experience. Dig Dis Sci 2009;54:2519-22.
39. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: A 5-year follow-up. J Hepatol 2009;51:156-60.
40. Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010;24:588-92.
41. Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011;34:335-43.
42. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 2011;55:636-46.
43. Seikaly MG. Mycophenolate mofetil - is it worth the cost? The in-favor opinion. Pediatr Transplant 1999;3:79-82. (Pubitemid 29234297)
44. Heneghan MA, Al-Chalabi T, McFarlane IG. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother 2006;7:145-56.
45. Czaja AJ. Mycophenolate mofetil to the rescue in autoimmune hepatitis: A fresh sprout on the decision tree. J Hepatol 2009;51:8-10.
46. Clissold SP, Heel RC. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984;28:485-518. (Pubitemid 15211796)
47. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010;139:1198-206.
48. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994;8:585-90. (Pubitemid 24381357)
49. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119:1312-6.
50. Wiegand J, Schuler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005;25:927-34. (Pubitemid 41404011)
51. Csepregi A, Rocken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006;12:1362-6.
52. Zandieh I, Krygier D, Wong V, et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol 2008;22:388-92. (Pubitemid 351772333)
53. Geier A, Gartung C, Dietrich CG, et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: Influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003;9:2681-5. (Pubitemid 38054439)
54. Lohse AW, Gil H. Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment. J Hepatol 2011;54:837-9.
55. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology 2010;139:58-72.
56. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology 2004;39:1066-74. (Pubitemid 38428946)
57. Holdener M, Hintermann E, Bayer M, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 2008;205:1409-22. (Pubitemid 351831496)
58. Manns MP. Autoimmune hepatitis: The dilemma of rare diseases. Gastroenterology 2011;140:1874-6.